The Merck collab would count as Leap's first of planned studies with immunotherapies, but the collaboration is not Keytruda's first rodeo.
Here are the names.
It just isn't as useful or descriptive right now.
Merck is extending this week's impressive rally and will soon retest the 2017 highs.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.